EyePoint Pharmaceuticals (NASDAQ: EYPT) was initiated with an Outperform rating and $33 per share price target at Baird on Friday ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Hot List New Coverage

EyePoint Pharmaceuticals (EYPT) Halted on Volatility, Up 67%April 21, 2023 10:19 AM EyePoint Pharmaceuticals (EYPT) Climbs 38% Following Outperform RatingApril 21, 2023 10:15 AM After-hours movers: ContextLogic gains on buyback, CSX up on EPSApril 20, 2023 5:42 PM Baird Starts EyePoint Pharmaceuticals, Inc. (EYPT) at OutperformApril 20, 2023 4:19 PM